Celldex Therapeutics, Inc. (FRA:TCE2)

Celldex Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,482	1,619	1,962	1,964	1,585	567
Market Cap Growth	-12.28%	-17.48%	-0.10%	23.89%	179.77%	1606.35%
Enterprise Value	982	892	1,752	1,665	1,216	407
Last Close Price	23.00	24.20	36.00	41.56	34.04	13.82
PS Ratio	668.85	238.82	315.12	890.64	387.68	93.45
PB Ratio	2.91	2.24	5.05	6.44	4.30	3.31
P/TBV Ratio	3.04	2.33	5.40	7.02	4.60	3.88
EV/Sales Ratio	-	131.57	281.34	754.94	297.37	67.06
Debt / Equity Ratio	0.00	0.01	0.01	0.01	0.01	0.02
Asset Turnover	0.00	0.01	0.02	0.01	0.01	0.04
Quick Ratio	12.55	18.38	13.69	16.41	24.71	13.81
Current Ratio	13.01	18.92	13.87	17.07	24.86	13.93
Return on Equity (ROE)	-32.44%	-26.84%	-37.45%	-30.13%	-22.43%	-39.41%
Return on Assets (ROA)	-21.77%	-19.38%	-21.70%	-16.79%	-12.70%	-17.27%
Return on Capital (ROIC)	-23.04%	-20.62%	-23.30%	-17.78%	-13.60%	-19.96%
Return on Capital Employed (ROCE)	-42.60%	-25.90%	-32.70%	-32.10%	-16.20%	-22.40%
Earnings Yield	-12.92%	-9.42%	-6.52%	-5.35%	-3.91%	-8.62%
FCF Yield	-10.45%	-9.53%	-5.03%	-5.03%	-3.45%	-6.05%
Buyback Yield / Dilution	-9.16%	-32.91%	-3.33%	-9.37%	-44.64%	-104.31%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.